Circulating tumor cells' (CTC) biomarkers may become indicators for selection of therapy. The presence of androgen receptor (AR)-variant-positive CTCs may be markers indicating the need for switching therapy. Methods for AR-variant mRNA isolation from CTCs and confirmation of expression are critical factors needed for these techniques to be clinically applicable.See related article by Tagawa et al., p. 1880.
Bibliographical noteFunding Information:
This work was supported by NCI RO1CA174777 (to S.M. Dehm), Prostate Cancer Foundation (to S.M. Dehm, B. Montgomery, and S.R. Plymate), P50
This work was supported by NCI RO1CA174777 (to S.M. Dehm), Prostate Cancer Foundation (to S.M. Dehm, B. Montgomery, and S.R. Plymate), P50 CA097186 (to B. Montgomery and S.R. Plymate), and W81XWH-14-2-0183, W81XWH-15-1-0430, the Veterans Affairs Research Program, and NCI P01CA163227 (all to S.R. Plymate)
© 2018 American Association for Cancer Research.
- Neoplastic Cells, Circulating
- Prostatic Neoplasms, Castration-Resistant
- RNA, Messenger
- Receptors, Androgen
PubMed: MeSH publication types
- Research Support, Non-U.S. Gov't
- Research Support, U.S. Gov't, Non-P.H.S.
- Journal Article
- Research Support, N.I.H., Extramural